Atypical antipsychotic drugs (APDs) have been hypothesized to show reduced extrapyramidal side effects (EPS) due to their rapid dissociation from the dopamine D2 receptor. However, support for this hypothesis is limited to a relatively small number of observations made across several decades and under different experimental conditions. Here we show that association rates, but not dissociation rates, correlate with EPS. We measured the kinetic binding properties of a series of typical and atypical APDs in a novel time-resolved fluorescence resonance energy transfer assay, and correlated these properties with their EPS and prolactin-elevating liabilities at therapeutic doses. EPS are robustly predicted by a rebinding model that considers the microenvironment of postsynaptic D2 receptors and integrates association and dissociation rates to calculate the net rate of reversal of receptor blockade. Thus, optimizing binding kinetics at the D2 receptor may result in APDs with improved therapeutic profile.
Imbalances in dopamine signaling are believed to play an integral part in the symptoms of schizophrenia. The efficacy of all currently marketed antipsychotic drugs (APDs) is thought to be mediated by attenuation of dopamine transmission through their actions as antagonists or low efficacy partial agonists at the dopamine D2 receptor (D2R)1, 2. However, the therapeutic window, i.e., the margin between the therapeutic dose and the dose that produces adverse side effects, varies considerably across these drugs1,2,3,4,5,6.
Extrapyramidal motor symptoms (e.g., acute dystonia and parkinsonian symptoms such as bradykinesia and tremor) and excess prolactin release are major adverse side effects of APDs mediated by blockade of D2R signaling in the nigrostriatal dopamine system and the tuberoinfundibular pathway, respectively1,2,3,4,5,6. Many “typical” or first-generation antipsychotics (FGAs) exhibit a relatively narrow therapeutic window with respect to these “on-target” side effects. The term “atypical” was first applied to clozapine, an efficacious APD with markedly lower “on-target” side effects when compared to FGAs, but that carries the risk for agranulocytosis, a potentially life-threatening off-target toxicity. From the study of clozapine and FGAs emerged second-generation antipsychotics (SGAs) designed to exhibit wider therapeutic windows3. However, certain SGAs first introduced as atypical have in subsequent studies been shown to have therapeutic indices more consistent with typical APDs with the converse also true for FGA/typical APDs, such as melperone7. What is apparent is that despite more than 50 years of pharmacological research into APDs, on-target side effects remain a significant problem, often resulting in poor drug compliance. Thus, understanding their cause is a critical step toward the design of better therapeutics2, 3, 8.
Several different pharmacological theories have been proposed to account for the atypicality of SGAs. One proposed mechanism is antagonism of the 5-HT2A receptor, which is thought to “balance” striatal dopamine signaling and thus reduce extrapyramidal side effects (EPS)9,10,11. However, the observation that the SGA amisulpride, which is considerably more D2 selective over 5-HT2A yet still exhibits reduced EPS, suggests that this theory cannot account for all examples of atypicality12, 13.
Another enduring theory of atypicality is based on the dissociation kinetics of APDs from the D2R. This concept originated from the observation that some atypical APDs have lower affinity for the D2R than typical APDs14,15,16, which was later demonstrated to be due to a faster dissociation rate17,18,19. This led Seeman and Kapur to propose the “fast off hypothesis,” whereby rapid dissociation from the D2R contributes to the reduced side effect profile of atypical APDs13. Key to this hypothesis is the rapid and transient nature of synaptic dopamine signaling. Rapid dissociation of an antagonist will allow a greater fraction of D2Rs to be bound by the transiently high local concentrations of released dopamine, therefore out-competing the antagonist in a surmountable fashion. In contrast, an antagonist with a slow dissociation rate is unlikely to dissociate from the D2R in the short time frame between dopamine release and re-uptake, blocking the receptor regardless of the local concentration of dopamine that is achieved, i.e., making the antagonism effectively insurmountable20.
The link between dissociation rate and “atypicality” has been questioned, however, based in part on the fact that the atypical APD olanzapine has relatively high affinity for the D2R and should, in theory, dissociate as slowly from the D2R as the typical APD haloperidol3. This inference is based on the widely held assumption that APDs exhibit similar association rates (k on) for the D2R and therefore that affinity is essentially driven by differences in dissociation rate. Although association rates have widely been assumed to be diffusion limited, we recently found that the association rates differ by several orders of magnitude across a range of structurally diverse D2R agonists21, demonstrating that the mechanisms that determine association rate can vary greatly with ligand structure.
The majority of drug-receptor-binding models assume free diffusion of analytes such that the dynamics of the system are reaction-limited. In certain tissue microenvironments, however, this assumption may not be valid, due, in part, to limitations on free diffusion arising from physical barriers. For example, the small aqueous compartment within a dopamine synapse (estimated to be 0.09–0.4 μm3)22 is unlikely to mix well with the bulk aqueous phase surrounding the synapse under the temporal and spatial scales over which neurotransmission operates. This may have important implications with regard to the blockade of dopamine synaptic signals and the ability of APDs to rebind free receptors. Rebinding in this case describes the process whereby a reversibly bound ligand dissociates from a receptor into the local aqueous environment but then rebinds the same or a nearby receptor before it is able to diffuse from the synaptic cleft23, effectively maintaining a higher concentration of the drug near the receptor. Under these conditions, the degree to which an individual drug rebinds is determined by receptor density, the association rate constant, and anatomical and physicochemical factors affecting the diffusion of the ligand away from the receptor24.
Currently available equilibrium and kinetic data on the binding of APDs to the D2R were derived over the past several decades using an assortment of different methods. The most common method has been to use radiolabeled compounds18, 19, 25, although not all APDs are available as radioligands. Alternatively, competition association assays formulated with a single radioligand/tracer can enable the kinetics of unlabeled ligands to be calculated26, 27. We have recently developed such an assay utilizing time-resolved fluorescence resonance energy transfer (TR-FRET) to measure the binding kinetics of unlabeled D2R agonists21, 28. In the present study, we use this method to determine the kinetics of an extensive series of APDs under physiological temperature and sodium ion concentration, and in doing so explore the kinetic basis for on-target side effects. We find that association rates, but not dissociation rates, correlate with EPS. EPS were predicted by a rebinding model that integrates association and dissociation rates within the microenvironment of postsynaptic D2Rs to calculate the net rate of reversal of receptor blockade. In contrast, prolactin elevation was directly correlated with APD off-rate from D2R. Thus, optimizing binding kinetics at the D2R may result in APDs with improved therapeutic profile.
Characterization of PPHT-red binding
Specific binding of the agonist PPHT-red to human D2L receptor (hD2LR) expressed in CHO membranes was saturable and best described by the interaction of the fluorescent ligand with a single population of binding sites (Fig. 1a). From these studies, the equilibrium dissociation constant (K d) of PPHT-red was determined to be 16.3 ± 0.9 nM. The expression level of the hD2LR recombinantly expressed in CHO cells was assessed, using [3H]-spiperone saturation binding and determined to be 1.13 ± 0.11 pmol mg−1 protein.
The binding kinetics of PPHT-red were characterized by monitoring the observed association rates at six different ligand concentrations (Fig. 1b). The observed rate of association was related to PPHT-red concentration in a linear fashion (Fig. 1c). Kinetic rate parameters for PPHT-red were calculated by globally fitting the association time courses, resulting in a k on of 2.3 ± 0.14 × 107 M−1 min−1 and a k off of 0.33 ± 0.01 min−1. The resulting K d (k off/k on) of 15.4 ± 0.11 nM was comparable to that obtained from the equilibrium studies. Ligand dissociation estimated directly through addition of an excess of haloperidol revealed a k off value of 0.52 ± 0.04 min−1, which was in good agreement with the value estimated from the global association time course described above (Fig. 1d).
The binding affinity of the various ligands for the hD2LR was measured at equilibrium at 37 °C in a buffer containing 5′-guanylyl imidodiphosphate (GppNHp) (0.1 mM) to ensure that antagonist binding only occurred to the G protein-uncoupled form of the receptor. Binding affinities (K i values) for the APDs studied are summarized in Table 1, and representative competition curves are presented in Fig. 2a. In this table we have separated APDs into those described in literature as typical APDs, those described as atypical and, in a third group, those that have been described as both typical and atypical.
Representative kinetic competition curves for selected D2R ligands are shown in Fig. 2b–d. Progression curves for PPHT-red alone and in the presence of competitor were globally fitted to Eq. 3 enabling the calculation of both k on (k3) and k off (k4) for each of the ligands, as reported in Table 1.
There was a very wide range in dissociation rates for the different ligands, with t ½ values between 0.32 min for chlorpromazine to 38.5 min for nemonapride. To validate the rate constants, the kinetically derived dissociation constant (K d) values (k off/k on) were compared with the dissociation constant (K i) obtained from equilibrium competition binding experiments (see Supplementary Fig. 1). There was a very good correlation between these two values for all APDs tested (two-tailed Pearson’s correlation r 2 = 0.98, P < 0.0001) indicating the kinetic parameters were accurate. Previous radioligand-binding studies have reported differences in dissociation rates of the order of 100-fold between the typical APD chlorpromazine and the atypical drugs, clozapine and quetiapine18, 19, 29; however, the present study did not corroborate these findings. The most plausible explanation for the differences observed between this and the original studies is the use of different temperatures to study the kinetics of these compounds coupled with the use of a subsaturating concentration of dopamine (100 nM) as the cold competing ligand, which may not be sufficient to fully prevent rebinding of the radioligand18, 29, 30.
Comparing kinetics and on-target side effects of APDs
Historically, the link between APD D2R affinity and dissociation rate is based on the assumption that APDs exhibit approximately the same k on for D2Rs19. However, we observed an increased range in k on values between the atypical APDs compared to a relatively small range in k off values. In contrast, for typical APDs there was a much narrower variation in the value of k on and differences in affinity were driven instead by changes in k off. Notably, however, the typical APD chlorpromazine exhibits k off values similar to, or indeed faster than atypical APDs (Table 1).
We have correlated our kinetic binding data with clinical findings taken from a recent meta-analysis of multiple-treatments studies comparing side effect profiles across a diverse group of APDs31. Both prolactin elevation and EPS are “on-target” adverse side effects related to D2R blockade, whereas adverse effects, such as QT interval and sedation, are generally considered “off-target” effects.
In contrast with the “rapid dissociation hypothesis”13, the kinetic k on, but not k off, was positively correlated with the incidence of EPS (Fig. 3a, b, Spearman’s r s = 0.68, P < 0.05 and r s = −0.13, P = 0.68, respectively). On the other hand, prolactin increases were correlated with the kinetic k off but not the k on (see Fig. 3d, c, Spearman’s r s = −0.82, P < 0.05 and r s = 0.12, P = 0.78, respectively). An obvious outlier is the atypical APD aripiprazole, which displays an extremely slow k off 21 but displays very little propensity to cause prolactin release. It should be noted that the mechanism of action of aripiprazole is different from other APDs in that it is a low efficacy partial agonist32, 33. As expected, QT prolongation, an off-target side effect, correlated neither with k on nor k off (Spearman’s r s = 0.09, P = 0.81 and r s = 0.30, P = 0.41, respectively; see Supplementary Fig. 2a, b).
The majority of studies covered in the Leucht et al.31 meta-analysis included as subjects chronically ill patients with a history of APD exposure, which has been previously shown to change D2R availability34. To address this issue, we used data from available multiple treatment studies in first-episode patients to test correlations of k on and k off with EPS odds ratios (ORs) in patients with minimal or no APD exposure. For the APDs tested in these studies, we found that ORs of EPS were robustly predicted by k on (Spearman’s r s = 0.90, P < 0.01) but not significantly related to k off (Spearman’s r s = −0.50, P = 0.22, see Fig. 3e, f).
Modeling rebinding at the D2R
Synapses are essentially minute gaps across which a neurotransmitter diffuses and as such can be considered receptor micro-compartments. While dopamine terminals rarely form classical synapses, they do form appositions with D2R-expression domains of target neurons that likely impose diffusion constraints on drugs in these regions35, 36.
Models of receptor rebinding in situations with limited diffusion allow the effect of k on and k off on the reversal of antagonist receptor occupancy to be considered collectively to derive an overall reversal rate (k r) that provides a measure of the local duration of antagonist effect24. The potential for rebinding of APDs was modeled according to two different scenarios; under conditions of limited diffusion (see Fig. 4a) such as those encountered at the level of a synapse; or with free diffusion (see Fig. 4b). In accordance with our current understanding of the rebinding process, k on was the dominant factor in determining the duration of target–receptor occupancy under conditions of limited diffusion. In contrast, k on had little effect on-target residency under conditions of free diffusion.
Consistent with our model, the correlation between k on and the incidence of EPS observed in the Leucht study was mirrored by the reversal rate k r, suggesting that k on is important in dictating the reversal of D2R occupancy at the level of the synapse (Spearman’s r s = −0.64, P < 0.05, see Fig. 4c). Interestingly, this correlation was marginally stronger for first-episode patients receiving APDs (Spearman’s r s = −0.95, P < 0.01, see Fig. 4d). In contrast, k r was not significantly correlated with elevations of prolactin (which is in agreement with the lack of correlation with k on) (Spearman’s r s = −0.17, P = 0.68, see Fig. 4e).
The novel TR-FRET kinetic assay described herein has a significantly improved throughput relative to more traditional radioligand binding assays. This has enabled us to accurately quantify, for the first time, the kinetic rate constants of a large number of unlabeled dopamine D2 antagonists under identical test conditions, allowing us to better investigate a role for kinetics in the side effect liability of clinically used APDs.
It has been widely assumed that association rates for APDs are diffusion limited and therefore comparable, meaning that the dissociation rate determines their affinity37, 38. Our TR-FRET data, however, revealed a surprisingly wide range of both association and dissociation rates across the ligands studied, demonstrating the importance of directly measuring rate constants. For example, the suggestion that the high-affinity atypical APDs olanzapine and risperidone should have k off values similar to haloperidol3 is not supported by our kinetic data.
We correlated our new kinetic binding data with clinical data that quantified the level of extrapyramidal side effects and hyperprolactinemia associated with a diverse group of clinical APDs. The clinical data were taken from a recent and relatively comprehensive multiple-treatment meta-analyses of antipsychotic drug efficacies31 and a summary of the primary literature on studies of drug-free patients. While meta-analytic methods assure the best control for the quality of the data across studies, it is important to note that because their focus was efficacy, EPS were often not a well-controlled outcome of the studies included in the meta-analysis. Indeed, the present models, like preceding hypotheses on EPS, are limited by the relative paucity of studies comparing antipsychotic drugs in which EPS are a primary outcome controlled for the minimum dose required to treat the psychosis or for adjunct treatments. To address this, we performed an additional exploratory analysis of studies in first episode or early psychosis, drug-free patients.
Consistent with the fast-dissociation hypothesis of APD atypicality, we found that hyperprolactinemia was correlated with the dissociation rate (k off), with ligands that were the slowest to dissociate from the D2R displaying the greatest liability for prolactin elevation in patients. Surprisingly, however, we found it was k on and not k off that was correlated with the incidence of EPS. Thus, drugs that bind more rapidly have greater liability of EPS, challenging the hypothesis that dissociation rate is the sole determinant of a compound’s liability to produce this side effect13. To illustrate, the typical APD chlorpromazine has a k off value similar to that of clozapine, but has much greater EPS liability. The increased propensity for EPS of chlorpromazine relates instead to its rapid association rate (k on). A recent study by Sahlholm and colleagues is consistent with this interpretation. These authors used D2R-evoked potassium channel activation to estimate receptor kinetics39, 40. Interestingly, the off rates determined by this indirect measurement, which were broadly consistent with the values obtained in the current study, did not distinguish between the typical and atypical APDs.
To further explore this finding, we employed a more holistic model of receptor binding that integrates both the association and dissociation rates in a system mimicking the environment of the synapse. This model assumes that diffusion of the drug out of the synapse is reduced by the physical barriers created by the pre- and post-synaptic membranes, effectively creating a compartment separate from the bulk aqueous phase. The consequence of this is that freshly dissociated ligands tend to remain in close proximity with membrane surfaces for longer, increasing the probability of a second binding event to the same or nearby receptor24. By using our measured association and dissociation rates in this model, we have estimated the overall relative rate of reversal of receptor blockade, termed k r 24.
As illustrated in Fig. 4, compounds with similar affinity and/or k off do not share the same potential to rebind receptors, a process which in the face of limited diffusion and subsaturating dopamine concentrations is governed largely by k on. Remarkably when we calculated the receptor reversal rate k r for each APD using the measured kinetic parameters, we found that this parameter was significantly correlated with the incidence of EPS, (Spearman’s r s = −0.64, P < 0.05 see Fig. 4c). The active standardized mean difference (SMD) produced a similar correlation with k on and k r, strongly suggesting that the process of rebinding and associated EPS liability may be a limiting factor for treatment effectiveness (see Supplementary Figs. 2c and 3a), ultimately leading to discontinuation of therapy (see Supplementary Figs. 2d and 3b). Intriguingly, the correlation of k r with EPS was stronger for the first-episode patients (Spearman’s r s = −0.95, P < 0.01 see Fig. 4c), which may reflect the fact that in this case EPS liability is taken from well-controlled study outcomes in patients receiving minimal adjunctive treatments.
We believe that there is no real improvement in correlation with k r over k on because for the particular properties of our model synapse, k on is the governing rate parameter for reversal of binding. In other systems, this might not be the case. For example, changes in the dimensions or receptor density of the compartment might reduce the impact of rebinding, meaning k r would be largely driven by k off. In these situations, it would be expected that k r would be better correlated to EPS than k on. Thus, k r represents a useful parameter with which to predict the receptor occupancy of a drug with known kinetic binding parameters under different degrees of limited diffusion.
Intriguingly, radioligand binding studies have demonstrated that subsaturating concentrations of dopamine less readily displace more rapidly associating radioligands, such as chlorpromazine, compared to more slowly associating radioligands, such as clozapine, despite their off rates being almost identical18. These observations taken together with our model indicate that rebinding maintains APD at a higher concentration in the synaptic (or appositional) compartment, resulting in a more effective competition for released dopamine. This, combined with the close correlation between rebinding rates and EPS, leads us to speculate that there is a minimum level of stimulation of postsynaptic D2Rs that must be maintained in order to avoid EPS. The ability of dopamine transmission to remain above this threshold in the presence of an APD is determined in large part by the APD’s rebinding rate. It is important, however, to acknowledge that the data presented in this study do not rule out alternative mechanisms that may contribute to the overall side effect profile of APDs, e.g., agonism at 5-HT1A 41.
Interestingly, and in contrast to EPS, prolactin elevation was not correlated with k r, reflecting the lack of correlation with k on. This may reflect that dopamine and APDs diffuse into the pituitary through the hypothalamic–pituitary portal system as opposed to a synaptic apposition42,43,44. Since ligands diffuse more freely around D2Rs on pituitary lactotrophs, their behavior conforms to the laws of mass action and rebinding may be negligible. As a consequence, the rate of reversal of APD-receptor occupancy, and thus excess prolactin release, will depend solely on the dissociation rate constant of APDs through the phenomenon of insurmountable antagonism.
To summarize, we propose to expand the kinetic hypothesis for APD side effects by considering not only the dissociation rate (and therefore propensity to display insurmountable antagonism), but also their association rate and potential for receptor rebinding, leading to increased competition with dopamine at the synapse (see Fig. 5a). Based on this scheme, we propose the following three broad classes of compounds to explain how these different kinetic characteristics may influence on-target side effects in different tissues:
Fast on, slow off compounds, e.g., haloperidol. The fast on rate results in a high receptor rebinding potential at D2Rs apposed to dopamine release sites in the striatum and therefore high EPS. In contrast, in the pituitary, the slow dissociation rate results in insurmountable antagonism at D2Rs leading to increased prolactin release.
Fast on, fast off compounds, e.g., chlorpromazine. Again, the fast on rate leads to high rebinding potential in the striatum and high EPS, but fast off rates result in surmountable antagonism and thus reduced propensity for hyperprolactinaemia.
Slow on, fast off compounds, e.g., clozapine. Slow on rates result in lower rebinding potential in the striatum and low EPS, and fast off rates lead to surmountable antagonism and reduced hyperprolactinemia.
This classification, summarized in Fig. 5b, suggests that slow on/fast off kinetics is the optimal kinetic profile for APDs targeting D2Rs. Notably, the APD with the slowest association rate is quetiapine, with a k on more than an order of magnitude slower than clozapine. Curiously, this compound has been found to be less efficacious than risperidone and olanzapine in treatment of chronic schizophrenia45. Quetiapine’s removal from the comparisons between k on and active SMD resulted in a much-improved correlation (Spearman’s r s = −0.85, P < 0.001; see Supplementary Fig. 2c), suggesting it may not produce sufficient rebinding for a robust clinical effect. This problem is likely to be further exacerbated by its short plasma half-life, which will further reduce its receptor coverage over the dosing period46.
Moreover, our model and the relative positions of compounds in Fig. 5a appear to help rationalize why certain compounds originally introduced as SGA/atypical APDs have typical profiles, e. g., zotapine, and conversely why drugs originally classified as FGA/typical APDs, such as melperone, are capable of displaying atypical behavior. The reality is that the side effects of APDs comprise multiple, pharmacologically separable effects, hence a more rational approach to classification is to consider a continuum based on the specific pharmacology of a given side effect rather than the current dichotomous system. This has lead us to speculate that there is likely to be a kinetic “sweet spot” where rebinding is sufficient for efficacy but not enough to cause EPS. Through optimization of these kinetic parameters, it may be possible to develop a new generation of safer drugs for a disease that still has high unmet medical need.
Tag-lite labeling medium (LABMED), SNAP-Lumi4-Tb, and the PPHT ((±)-2-(n-phenethyl-n-propyl)amino-5-hydroxytetralin hydrochloride;1-Naphthalenol,5,6,7,8-tetrahydro-6-[(2-phenylethyl)propylamino]) derivative labeled with a red fluorescent probe (PPHT-red) was obtained from Cisbio Bioassays (Bagnols-sur-Cèze, France). Ninety-six-well polypropylene plates (Corning) were purchased from Fisher Scientific UK (Loughborough, UK) and 384-well optiplate plates were purchased from PerkinElmer (Beaconsfield, UK). GppNHp, risperidone, chlorpromazine hydrochloride, quetiapine hemifumarate, ziprasidone hydrochloride monohydrate, zotepine, sertindole, thioridazine hydrochloride, fluphenazine dihydrochloride, molindone hydrochloride, loxapine succinate, perphenazine, trifluoperazine dihydrochloride, spiperone, (−)-sulpiride, droperidol, and (+)-butaclamol used in competition assays were obtained from Sigma-Aldrich (Poole, UK). Olanzapine, nemonapride, remoxipride hydrochloride, flupenthixol dihydrochloride, paliperidone, amisulpride, melperone hydrochloride, clozapine, raclopride, domperidone, asenapine maleate and haloperidol hydrochloride used for competition assays were obtained from Tocris Bioscience (Avonmouth, Bristol).
The host Chinese hamster ovary (CHO) K1 cell line was provided by Prof. J. Baker, University of Nottingham (ATCC #CCL-61). This was transfected with the cDNA encoding a SNAP-tagged human dopamine D2L receptor (Genbank ref.: NM_000795), and a stable dilution-cloned cell line (CHO–D2L) was established by zeocin resistance encoded by the plasmid vector (pcDNA3.1zeo+, Invitrogen, Paisley UK). Cells were maintained in Dulbecco’s modified Eagle’s medium: Ham F12 (DMEM:F12) containing 2 mM glutamine (Sigma-Aldrich, Poole, UK) and supplemented with 10% fetal calf serum (Life Technologies, Paisley UK).
Terbium labeling of SNAP-tagged D2L cells
Cell culture medium was removed from the t175 cm2 flasks containing confluent adherent CHO–D2L cells. Twelve milliliter of Tag-lite labeling medium containing 100 nM of SNAP-Lumi4-Tb was added to the flask and incubated for 1 h at 37 °C under 5% CO2. Cells were washed 2× in PBS (GIBCO Carlsbad, CA) to remove the excess of SNAP-Lumi4-Tb then detached using 5 ml of GIBCO enzyme-free Hank’s-based cell dissociation buffer (GIBCO, Carlsbad, CA) and collected in a vial containing 5 ml of DMEM:F12 containing 2 mM glutamine (Sigma-Aldrich) and supplemented with 10% fetal calf serum. Cells were pelleted by centrifugation (5 min at 1500 rpm) and the pellets were frozen to −80 °C. To prepare membranes, homogenization steps were conducted at 4 °C (to avoid receptor degradation). Specifically 20 ml per t175-cm2 flask of wash buffer (10 mM HEPES and 10 mM EDTA, pH 7.4) was added to the pellet. This was homogenized using an electrical homogenizer Ultra-Turrax (Ika-Werk GmbH & Co. KG, Staufen, Germany) (position 6, 4 × 5-s bursts) and subsequently centrifuged at 48,000×g at 4 °C (Beckman Avanti J-251 Ultracentrifuge; Beckman Coulter, Fullerton, CA) for 30 min. The supernatant was discarded, and the pellet was re-homogenized and centrifuged as described above in wash buffer. The final pellet was suspended in ice-cold 10 mM HEPES and 0.1 mM EDTA, pH 7.4, at a concentration of 5–10 mg ml−1. Protein concentration was determined using the bicinchoninic acid assay kit (Sigma-Aldrich), using BSA as a standard and aliquots maintained at −80 °C until required. Prior to their use, the frozen membranes were thawed and the membranes suspended in the assay buffer at a membranes concentration of 0.2 mg ml−1.
[3H]-Spiperone saturation binding assays
Increasing concentrations of [3H]-spiperone (0.020−1.2 nM) were incubated with human D2L CHO cell membranes (10 μg per well) at 37 °C in assay binding buffer (20 mM HEPES 138 mM NaCl. 6 mM MgCl2, 1 mM EGTA, and 1 mM EDTA pH 7.4) containing 100 μM GppNHp and 0.1% ascorbic acid in a 1 ml reaction volume. Non-specific binding was determined in the presence of 3 μM (+)-butaclamol. After a 2 h incubation period, bound and free [3H]-spiperone were separated by fast-flow filtration through GF/B filters using a Filter Mate Harvester (PerkinElmer) followed by 2 ml wash with ice-cold PBS (Lonza). After drying, filter bound radioactivity was measured following addition of 40 μl of Microscint 20 (PerkinElmer) using a Topcount microplate scintillation counter (PerkinElmer). Aliquots of [3H]-spiperone were also quantified accurately to determine how much radioactivity was added to each well using liquid scintillation spectrometry on a Tri-Carb liquid scintillation counter (PerkinElmer).
Fluorescent ligand-binding assays
All fluorescent binding experiments using PPHT-red were conducted in white 384-well Optiplate plates, in assay binding buffer, 20 mM HEPES, 138 mM NaCl, 6 mM MgCl2, 1 mM EGTA, and 1 mM EDTA and 0.02% pluronic acid pH 7.4, 100 μM GppNHp, and 0.1% ascorbic acid. GppNHp was included to remove the G protein-coupled population of receptors that can result in two distinct populations of binding sites in membrane preparations, since the Motulsky–Mahan model26 is only appropriate for ligands competing at a single site. In all cases, nonspecific binding was determined in the presence of 10 μM haloperidol.
Determination of PPHT-red binding kinetics
To accurately determine association rate (k on) and dissociation rate (k off) values, the observed rate of association (k ob) was calculated using at least four different concentrations of PPHT-red. The appropriate concentration of PPHT-red was incubated with human D2L CHO cell membranes (2 μg per well) in assay binding buffer (final assay volume, 40 μl). The degree of PPHT-red bound to the receptor was assessed at multiple time points by HTRF detection to allow construction of association kinetic curves. The resulting data were globally fitted to the association kinetic model (Eq. 2) to derive a single best-fit estimate for k on and k off as described under data analysis.
Competition binding kinetics
To determine the association and dissociation rates of D2R ligands, we used a competition kinetic binding assay we recently described to profile the kinetics of a series of D2R agonists21. This approach involves the simultaneous addition of both fluorescent ligand and competitor to the receptor preparation, so that at t = 0 all receptors are unoccupied. 12.5 nM PPHT-red (a concentration which avoids ligand depletion in this assay volume, see Carter et al.,47 was added simultaneously with the unlabeled compound (at t = 0) to CHO cell membranes containing the human D2LR (2 μg per well) in 40 μl of assay buffer. The degree of PPHT-red bound to the receptor was assessed at multiple time points by HTRF detection.
Nonspecific binding was determined as the amount of HTRF signal detected in the presence of haloperidol (10 μM) and was subtracted from each time point, meaning that t = 0 was always equal to zero. Each time point was conducted on the same 384-well plate incubated at 37 °C with orbital mixing (1 s of 100 RPM per cycle).
Multiple concentrations of unlabeled competitor were tested for determination of rate parameters. Data were globally fitted using Eq. (3) to simultaneously calculate k on and k off. Different ligand concentration ranges were chosen, as compounds with a long residence time equilibrate more slowly, so a higher relative concentration is required to ensure the experiments reach equilibrium within a reasonable time frame (120 min), while still maintaining a good signal to noise.
Signal detection and data analysis
Signal detection was performed on a Pherastar FS (BMG Labtech, Offenburg, Germany) using standard HTRF settings. The terbium donor was always excited with three laser flashes at a wavelength of 337 nm. A kinetic TR-FRET signal was collected at 20 s intervals both at 665 and 620 nm, when using red acceptor. HTRF ratios were obtained by dividing the acceptor signal (665 nm) by the donor signal (620 nm) and multiplying this value by 10,000. Probe dissociation rates were analyzed by displacement of the tracer with a large excess of an unlabeled ligand known to bind to the same site with similar or higher affinity.
All experiments were analyzed by non-regression using Prism 6.0 (GraphPad Software, San Diego, USA). Competition displacement binding data were fitted to sigmoidal (variable slope) curves using a “four parameter logistic equation”:
IC50 values obtained from the inhibition curves were converted to K i values using the method of Cheng and Prusoff48. PPHT-red association data were fitted as follows to a global fitting model using GraphPad Prism 6.0 to simultaneously calculate k on and k off using the following equation, where k ob equals the observed rate of association:
Association and dissociation rates for unlabeled antagonists were calculated using the equations described by Motulsky and Mahan26:
Where: X = Time (min), Y = Specific binding (HTRF ratio 665 nm/620 nm×10,000), k 1 = k on PPHT-red, k 2 = k off PPHT-red, L = Concentration of PPHT-red used (nM), B max = Total binding (HTRF ratio 665 nm/620 nm×10,000), I = Concentration of unlabeled antagonist (nM). Fixing the above parameters allowed the following to be calculated: k 3 = Association rate of unlabeled ligand (M−1 min−1), k 4 = Dissociation rate of unlabeled ligand (min−1). Dissociation of PPHT-red was fitted to a one phase mono-exponential decay function to estimate the dissociation rate of PPHT-red directly. Specific binding was determined by subtracting the nonspecific HTRF ratio from the total HTRF ratio.
Rebinding describes the ability of a drug molecule to bind to multiple receptors within a compartment before diffusing away into bulk, the overall effect being extended target–receptor occupancy24. To examine this, we utilized a model of an immunological synapse with a compartment volume of 0.176 μm3, which is within the range described for the dopamine synapse49. In this model, the overall macroscopic reversal rate (k r) is described by the following equation:
where k off = dissociation rate from the receptor, k on = association rate onto the receptor, R = surface receptor density fixed at 1 × 1011 cm−2, and k - = the diffusion rate out of the synaptic compartment into bulk aqueous, fixed at 1.2 × 10−5 cm s−1. All data were analyzed using GraphPad Prism 6.0.
Comparing binding kinetics and clinical side effect profile
To explore the role of kinetics in determining on-target side effect liability, we correlated the kinetic values determined in this study with published clinical data taken from a comprehensive meta-analysis of clinically used APDs performed by Leucht and colleagues31. The majority of studies covered in the Leucht et al. meta-analysis included as subjects chronically ill patients with a history of APD exposure and the potential for modified D2R availability. To address this, we repeated the above analysis with reported data from available multiple-treatments studies in early psychosis patients who entered studies with minimal exposure to APDs50,51,52,53,54,55,56,57. Odds ratios for APD-induced EPS relative to spontaneous EPS in untreated patients were calculated as follows: % APD-treated with EPS × % untreated without EPS/% APD-treated without EPS × % untreated with spontaneous EPS. Unless otherwise stated, correlation analyses were performed using a two-tailed Spearman rank correlation allowing the calculation of the correlation coefficient, r s. Although this analysis does not assume a linear relationship, a simple trend line has been added to illustrate the positive or negative association between the two variables. Differences were considered significant at P < 0.05. All analysis were performed using GraphPad Prism 6.0.
The data that support the findings of this study are available from the corresponding author on reasonable request.
Ginovart, N. & Kapur, S. Role of dopamine D(2) receptors for antipsychotic activity. Handb. Exp. Pharmacol. 212, 27–52 (2012).
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W. & Lieberman, J. A. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry 17, 1206–1227 (2012).
Meltzer, H. Y. Update on typical and atypical antipsychotic drugs. Annu. Rev. Med. 64, 393–406 (2013).
Leucht, S. et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31–41 (2009).
Farde, L. et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 49, 538–544 (1992).
Caron, M. G. et al. Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H]dihydroergocryptine binding with the dopaminergic control of prolactin release. J. Biol. Chem. 253, 2244–2253 (1978).
Meltzer, H. Y., Matsubara, S. & Lee, J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251, 238–246 (1989).
Perkins, D. O. Predictors of noncompliance in patients with schizophrenia. J. Clin. Psychiatry 63, 1121–1128 (2002).
Janssen, P. A. et al. Pharmacology of risperidone (R 64,766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J. Pharmacol. Exp. Ther. 244, 685–693 (1998).
Meltzer, H. Y., Matsubara, S. & Lee, J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251, 238–246 (1989).
Roth, B. L., Sheffler, D. J. & Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3, 353–359 (2004).
Martinot, J. L. et al. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology 124, 154–158 (1996).
Kapur, S. & Seeman, P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry 158, 360–369 (2001).
Burki, H. R. Effects of fluperlapine on dopaminergic systems in rat brain. Psychopharmacology 89, 77–84 (1986).
Seeman, P., Corbett, R., Nam, D. & Van Tol, H. H. M. Dopamine and serotonin receptors: amino acid sequences, and clinical role in neuroleptic parkinsonism. Jpn J. Pharmacol. 71, 187–204 (1996).
Seeman, P., Corbett, R. & Van Tol, H. H. M. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacol 16, 93–110 (1997).
Seeman, P. & Tallerico, T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol. Psychiatry 3, 123–134 (1998).
Seeman, P. & Tallerico, T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am. J. Psychiatry 156, 876–884 (1999).
Kapur, S. & Seeman, P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J. Psychiatry Neurosci. 25, 161–166 (2000).
Charlton, S. J. & Vauquelin, G. Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays. Br. J. Pharmacol. 161, 1250–1265 (2010).
Klein Herenbrink, C. et al. The role of kinetic context in apparent biased agonism at GPCRs. Nat. Commun. 7, 10842 (2016).
Rice, M. E. & Cragg, S. J. Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway. Brain Res. Rev. 58, 303–313 (2008).
Lagerholm, B. C. & Thompson, N. L. Theory for ligand rebinding at cell membrane surfaces. Biophys. J. 74, 1215–1228 (1998).
Vauquelin, G. & Charlton, S. J. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br. J. Pharmacol. 161, 488–508 (2010).
Langlois, X. et al. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia. J. Pharmacol. Exp. Ther. 342, 91–105 (2012).
Motulsky, H. J. & Mahan, L. C. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol. Pharmacol. 25, 1–9 (1984).
Carboni, L. et al. Slow dissociation of partial agonists from the D2 receptor is linked to reduced prolactin release. Int. J. Neuropsychopharmacol. 15, 645–656 (2012).
Albizu, L. et al. Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat. Chem. Biol. 6, 587–594 (2010).
Seeman, P. An update of fast-off dopamine D2 atypical antipsychotics. Am. J. Psychiatry 162, 1984–1985 (2005).
Seeman, P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 47, 27–38 (2000).
Leucht, S. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382, 951–962 (2013).
Shapiro, D. A. et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28, 1400–1411 (2003).
Yokoi, F. et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27, 248–259 (2002).
Tarazi, F. I., Zhang, K. & Baldessarini, R. J. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J. Pharmacol. Exp. Ther. 297, 711–717 (2001).
Ribrault, C., Sekimoto, K. & Triller, A. From the stochasticity of molecular processes to the variability of synaptic transmission. Nat. Rev. Neurosci. 12, 375–387 (2011).
Descarries, L., Watkins, K. C., Garcia, S., Bosler, O. & Doucet, G. Dual character, asynaptic and synaptic, of the dopamine innervation in adult rat neostriatum: a quantitative autoradiographic and immunocytochemical analysis. J. Comp. Neurol. 375, 167–186 (1996).
Roth, B. L., Sheffler, D. & Potkine, S. G. Atypical antipsychotic drug actions: unitary or multiple mechanisms for ‘atypicality’? Clin. Neurosci. Res. 3, 108–117 (2003).
Horacek, J. et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20, 389–409 (2006).
Sahlholm, K. et al. Typical and atypical antipsychotics do not differ markedly in their reversibility of antagonism of the dopamine D2 receptor. Int. J. Neuropsychopharmacol. 17, 149–155 (2013).
Sahlholm, K. et al. The fast-off hypothesis revisited: a functional kinetic study of antipsychotic antagonism of the dopamine D2 receptor. Eur. Neuropsychopharmacol. 26, 467–476 (2016).
Newman-Tancredi, A. & Kleven, M. S. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology 216, 451–473 (2011).
MacLeod, R. M., Fontham, E. H. & Lehmeyer, J. E. Prolactin and growth hormone production as influenced by catecholamines and agents that affect brain catecholamines. Neuroendocrinology 6, 283–294 (1970).
Kamberi, I. A., Mical, R. S. & Porter, J. C. Prolactin-inhibiting activity in hypophysial stalk blood and elevation by dopamine. Experientia 26, 1150–1151 (1970).
Mansour, A. et al. Localization of dopamine D2 receptor mRNA and D1 and D2 receptor binding in the rat brain and pituitary: an in situ hybridization receptor autoradiographic analysis. J. Neurosci. 10, 2587–2600 (1990).
Asmal, L. et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 11, CD006625 (2013).
Handley, S. A., Bowskill, S. V., Patel, M. X. & Flanagan, R. J. Plasma quetiapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2000–2011. Ther. Adv. Psychopharmacol 3, 129–137 (2013).
Carter, C. M., Leighton-Davies, J. R. & Charlton, S. J. Miniaturized receptor binding assays: complications arising from ligand depletion. J. Biomol. Screen. 12, 255–266 (2007).
Cheng, Y. & Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099–3108 (1973).
Coombs, D. & Goldstein, B. Effects of the geometry of the immunological synapse on the delivery of effector molecules. Biophys. J. 87, 2215–2220 (2004).
Crespo-Facorro, B. et al. Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison. J. Psychopharmacol. 25, 744–754 (2011).
Cuesta, M. J. et al. Spontaneous parkinsonism is associated with cognitive impairment in antipsychotic-naive patients with first-episode psychosis: a 6-month follow-up study. Schizophr. Bull. 40, 1164–1173 (2014).
Kahn, R. S. et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371, 1085–1097 (2008).
Lieberman, J. A. et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28, 995–1003 (2003).
Moller, H. J. et al. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German research network on Schizophrenia. Int. J. Neuropsychopharmacol. 11, 985–997 (2008).
Robinson, D. G. et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am. J. Psychiatry 163, 2096–2102 (2006).
Sanger, T. M. et al. Olanzapine versus haloperidol treatment in first-episode psychosis. Am. J. Psychiatry 156, 79–87 (1999).
Schooler, N. et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am. J. Psychiatry 162, 947–953 (2005).
Chakrabarti A. et al. Loxapine for schizophrenia. Cochrane Database Syst. Rev. CD001943 4, CD001943 (2007).
Glazer, W. M. Does loxapine have “atypical” properties? Clinical evidence. J. Clin. Psychiatry 60, 42–46 (1999).
Peluso, M. J., Lewis, S. W., Barnes, T. R. & Jones, P. B. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br. J. Psychiatry 200, 387–392 (2012).
Kose, E., Uno, K. & Hayashi, H. Evaluation of the expression profile of extrapyramidal symptoms due to antipsychotics by data mining of Japanese adverse drug event report (JADER) database. Yakugaku. Zasshi. 137, 111–120 (2017).
Tandon, R. et al. Section of pharmacopsychiatry, world psychiatric association pharmacopsychiatry section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res. 100, 20–38 (2008).
Röhricht, F., Gadhia, S., Alam, R. & Willis, M. Auditing clinical outcomes after introducing off-licence prescribing of atypical antipsychotic melperone for patients with treatment refractory schizophrenia. Sci. World J. 2012, 512047 (2012).
Popovic, D., Nuss, P. & Vieta, E. Revisiting loxapine: a systematic review. Ann. Gen. Psychiatry. 14, 15 (2015).
Bagnall, A., Fenton, M., Lewis, R., Leitner, M. L. & Kleijnen, J. Molindone for schizophrenia and severe mental illness. J.Cochrane Database Syst. Rev. 2, CD002083 (2002).
Aparasu, R. R., Jano, E., Johnson, M. L. & Chen, H. Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. Am. J. Geriatr. Pharmacother. 6, 198–204 (2008).
Sikich, L. et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am. J. Psychiatry. 165, 1420–1431 (2008).
Hemsley, K. M. & Crocker, A. D. Raclopride and chlorpromazine, but not clozapine, increase muscle rigidity in the rat: relationship with D2 dopamine receptor occupancy. Neuropsychopharmacology 21, 101–109 (1999).
Stone T. W. CNS Neurotransmitters and Neuromodulators: Dopamine (CRC Press, 1996).
Westerink, B. H. Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain? Eur. J. Pharmacol. 455, 1–18 (2002).
Thomas Roux (Cisbio Bioassays, Bagnols-sur-Cèze) for providing PPHT-red for the kinetic binding studies. Catherine Wark and Neil Cox (BMG Labtech Ltd.) for their expert technical assistance and BMG for personal sponsorship of David Sykes. H.M. is supported by a NIH Award P50 MH086404, New York State Office of Mental Health. J.A.J. is supported by Grants R01 MH54137 and K05 DA022413. The authors like to thank Dr. Scott Stroup for helpful discussion.
The authors declare no competing financial interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Sykes, D.A., Moore, H., Stott, L. et al. Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. Nat Commun 8, 763 (2017). https://doi.org/10.1038/s41467-017-00716-z
This article is cited by
Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review
Advances in Therapy (2022)
Low continuation of antipsychotic therapy in Parkinson disease – intolerance, ineffectiveness, or inertia?
BMC Neurology (2021)
Differences in cause and 12-month follow-up outcome of parkinsonian symptoms in depressed older adults treated with antipsychotics: a case series
BMC Psychiatry (2021)
A rebinding-assay for measuring extreme kinetics using label-free biosensors
Scientific Reports (2021)
The Benefits of Olanzapine in Palliating Symptoms
Current Treatment Options in Oncology (2021)
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.